Why AngioDynamics stock investors should watch NanoKnife’s move into benign prostate disease
FDA clearance to begin the RELIEF study opens a large benign prostatic hyperplasia opportunity for NanoKnife, but the small trial, general anaesthesia and crowded treatment market leave major commercial questions unanswered.